by Raynovich Rod | Jul 22, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Update 7/23 Biogen Idec (BIIB) Soars 11% on Earnings EPS at $3.49 vs est $2.83; Sales of MS drugs were $2.42B vs $1.72B last year. Our large cap portfolio is now up 15% YTD with less risk than mid and small caps. One analyst thinks PBYI will be acquired but watch out...
by Raynovich Rod | Jul 15, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Macro
Update 8PM EDT NASDAQ Holds Losses to 0.54%-Futures Stable Biotech Damage Across the Sector-Rayno Life Science Portfolio Notes Large Caps off about 2% (FBT), but Gilead (GILD) down only 0.95% and Roche (RHHBY) up 0.28%. Rayno Biopharma stocks all red down 3-4% with...
by Raynovich Rod | Jun 18, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update June 19.. 3:10 p EDT Ten Yr 2.62%, U.S.equities flat,biotech mixed, jobless claims down. Japanese and European equities up. Iraq on front page. GOLD Up $41 Breaks Through Resistance at $1300 Gold futures rose on technicals, Middle East turmoil, a weak dollar...
by Raynovich Rod | Jun 12, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
NASDAQ Off 0.8% On Disappointing Economic Data and Spiking Crude Islamic militants took major cities in Iraq causing a spike in oil to $106. The energy sector rallied 0.7% with many smaller players soaring over 4%. The energy sector is very strong up 10% YTD....
by Raynovich Rod | Feb 11, 2014 | Macro, Weather//Ski Reports-Western US
Update- 1 FEB 14 9:40a PST Back Peddling on Storm: usual High Pressure Ridge-Sheckter NOAA Shows Weakening Storm For Next Week Same for Unisys Model-Blocking High Intellicast 10 Day shows ppt diminishing ————– Pineapple Express Dumps on...
by Raynovich Rod | Feb 5, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Biotech Bull Market Intact But Technicals Rule On January 27 we reiterated our model for life science stocks for 2014. We will review each component of our model and where the sector stands after about a 5% correction off highs with the sector still up 6% YTD...
by Raynovich Rod | Jan 29, 2014 | Macro
Update 2/3/14 NetLaZon=$927 vs $979 down 5.3% since 1/29/14 =NFLX+TSLA+AMZN Momentum Still Rules With not much to say about biotech today except it appears unfazed by macro news (see BIIB $316 up 4%, MDVN $85 up 12%, ILMN $150 up 3.4%). Today I’ll delve...
by Raynovich Rod | Dec 19, 2013 | 2024-25 Life Science Portfolios, Macro
Taper Lite With Zero Interest Rates The big FED Meeting with the Bernanke farewell concluded with “taper lite”, optimism on the economy and continued low inflation. The FED decision to roll back its economic stimulus was welcomed by investors boosting the...
by Raynovich Rod | Nov 19, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Bull Market Intact But Momentum Stocks Taking Hits Most of you know the game. Buy stocks with headline news, new business models, increasing RSI and charts that scream momentum. Examples proliferate: Aegerion (AEGR), Celldex (CLDX), Netflix (NFLX), Tesla (TSLA), 3D...
by Raynovich Rod | Nov 12, 2013 | Macro
Isn’t A “Long Only” Hedge Fund A Mutual Fund? The news from Monday’s November 11 Wall Street Journal on p C1 is that hedge funds who are shorting stocks are underperforming the market and most mutual finds. In this article, Juliet Chung points...
